326 related articles for article (PubMed ID: 25764941)
1. Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma.
Rue SM; Eckelman BP; Efe JA; Bloink K; Deveraux QL; Lowery D; Nasoff M
Vet Immunol Immunopathol; 2015 Apr; 164(3-4):148-59. PubMed ID: 25764941
[TBL] [Abstract][Full Text] [Related]
2. Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma.
McLinden GP; Avery AC; Gardner HL; Hughes K; Rodday AM; Liang K; London CA
J Vet Intern Med; 2024; 38(3):1666-1674. PubMed ID: 38662527
[TBL] [Abstract][Full Text] [Related]
3. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation.
Impellizeri JA; Howell K; McKeever KP; Crow SE
Vet J; 2006 May; 171(3):556-8. PubMed ID: 16624725
[TBL] [Abstract][Full Text] [Related]
4. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
[TBL] [Abstract][Full Text] [Related]
5. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment.
Mizuno T; Kato Y; Kaneko MK; Sakai Y; Shiga T; Kato M; Tsukui T; Takemoto H; Tokimasa A; Baba K; Nemoto Y; Sakai O; Igase M
Sci Rep; 2020 Jul; 10(1):11476. PubMed ID: 32651429
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
7. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
8. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.
Flieger D; Renoth S; Beier I; Sauerbruch T; Schmidt-Wolf I
Cell Immunol; 2000 Aug; 204(1):55-63. PubMed ID: 11006018
[TBL] [Abstract][Full Text] [Related]
10. Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.
Weiskopf K; Anderson KL; Ito D; Schnorr PJ; Tomiyasu H; Ring AM; Bloink K; Efe J; Rue S; Lowery D; Barkal A; Prohaska S; McKenna KM; Cornax I; O'Brien TD; O'Sullivan MG; Weissman IL; Modiano JF
Cancer Immunol Res; 2016 Dec; 4(12):1072-1087. PubMed ID: 27856424
[TBL] [Abstract][Full Text] [Related]
11. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.
Natsume A; Shimizu-Yokoyama Y; Satoh M; Shitara K; Niwa R
Cancer Sci; 2009 Dec; 100(12):2411-8. PubMed ID: 19758394
[TBL] [Abstract][Full Text] [Related]
12. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma.
Jubala CM; Wojcieszyn JW; Valli VE; Getzy DM; Fosmire SP; Coffey D; Bellgrau D; Modiano JF
Vet Pathol; 2005 Jul; 42(4):468-76. PubMed ID: 16006606
[TBL] [Abstract][Full Text] [Related]
13. Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells.
Sakai O; Ogino S; Tsukui T; Igase M; Mizuno T
J Vet Med Sci; 2021 Oct; 83(10):1495-1499. PubMed ID: 34408098
[TBL] [Abstract][Full Text] [Related]
14. Canine CD20 gene.
Kano R; Inoiue C; Okano H; Yamazaki J; Takahashi T; Watari T; Tokuriki M; Hasegawa A
Vet Immunol Immunopathol; 2005 Dec; 108(3-4):265-8. PubMed ID: 16061290
[TBL] [Abstract][Full Text] [Related]
15. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
Tobinai K
Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
[TBL] [Abstract][Full Text] [Related]
16. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
Tobinai K
Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
Wu L; Wang C; Zhang D; Zhang X; Qian W; Zhao L; Wang H; Li B; Guo Y
Cancer Lett; 2010 Jun; 292(2):208-14. PubMed ID: 20056316
[TBL] [Abstract][Full Text] [Related]
18. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
19. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.
Gillies SD; Lan Y; Williams S; Carr F; Forman S; Raubitschek A; Lo KM
Blood; 2005 May; 105(10):3972-8. PubMed ID: 15692062
[TBL] [Abstract][Full Text] [Related]
20. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
